21st Apr 2016 11:11
LONDON (Alliance News) - GW Pharmaceuticals PLC said Thursday that the US Food and Drug Administration has granted an orphan drug designation for cannabidiol for the treatment of Tuberous Sclerosis Complex, a rare genetic disorder which commonly causes epilepsy as a symptom.
GW Pharmaceuticals said that this is the third orphan indication that it is targeting within its Epidiolex clinical development programme, which also includes four phase III trials in rare childhood epilepsies Dravet syndrome and Lennox-Gastaut syndrome.
An orphan drug designation is granted to drugs that treat a rare disease or condition that affects a small patient pool, and this designation allows for seven-year market exclusivity.
Shares in GW Pharmaceuticals were up 1.6% at 514.00 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L